Top 5 Pharmacy Times Alzheimer Disease Articles of 2023

1. FDA Converts Lecanemab-irmb to Full Approval for Treatment of Alzheimer Disease

Lecanemab-irmb is the first amyloid beta-directed antibody to be converted from an accelerated approval to a traditional approval for the treatment of Alzheimer disease. Read More Here.

ipopba - stock.adobe.com

2. Amyloid-Targeting Class of Alzheimer Disease Drugs Show Potential, Raise Concerns of Accessibility for Diverse Patients

Advancements in the development of amyloid-targeting monoclonal antibodies show promise for treating Alzheimer disease, but there have been concerns around cost, adverse reactions, and inequity in care for marginalized patients. Read More Here.

3. Study: Food Insecurity Associated With Increased Risk of Dementia

Food insecurity was associated with an increased risk of dementia, poorer memory function, and faster memory decline in older adults. Read More Here.

4. Study: Cholesterol in Brain Associated With Alzheimer Disease, Brain Damage

Investigators believe lowering cholesteryl ester levels could help prevent brain damage and behavioral changes, reducing the risk of Alzheimer disease. Read More Here.

5. Data Show Cognitive Consequences of Benzodiazepine Use

The drug may be a risk factor for dementia-related illnesses. Read More Here.